Intesticort

Budesonide, the active ingredient in Intesticort, is a glucocorticoid presented as a rectal dosage form for rectal use. It reduces inflammation in the colon and rectum, particularly in patients with ulcerative colitis and proctitis.

GNH USA supplies Intesticort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Intesticort is a glucocorticoid that targets inflammatory bowel disease affecting the colon and rectum.

- Ulcerative colitis: reduces mucosal inflammation and helps achieve clinical remission. - Proctitis: alleviates rectal inflammation and associated symptoms such as bleeding and urgency.

Common Side Effects: - Rectal irritation or burning sensation. - Itching or mild rash at the application site. - Discharge or spotting. - Headache. - Nausea. - Mild abdominal cramping.

Serious or Rare Side Effects: - Adrenal suppression leading to systemic corticosteroid effects. - Severe infection or sepsis. - Allergic reactions such as angioedema or anaphylaxis. - Colonic perforation. - Systemic glucocorticoid toxicity (e.g., hyperglycaemia, hypertension). - Vision changes or cataract formation.

Intesticort should be used under medical supervision with attention to the following precautions.

- Assess disease severity: confirm diagnosis of ulcerative colitis or proctitis before initiating therapy. - Monitor for infection: discontinue if systemic infection develops. - Caution with systemic steroids: avoid concurrent high‑dose systemic corticosteroids to reduce adrenal suppression risk. - Bowel obstruction: do not use in patients with known obstructive lesions. - Hypersensitivity: avoid in individuals with known allergy to budesonide or formulation excipients. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Intesticort may interact with other medicines; clinical judgment is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic budesonide exposure. - Systemic corticosteroids: additive immunosuppressive effects and adrenal suppression. - Immunosuppressants (e.g., azathioprine, methotrexate): heightened risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce therapeutic effect. - NSAIDs: increase risk of gastrointestinal irritation. - Anticholinergic agents: may affect bowel motility and drug absorption.